AHR and breast cancer: Moreover, overexpression of CYP1B1 is not known to activate the AHR, and treatment of breast cancer cell lines with 4-hydroxyestradiol, the primary estrogen product of CYP1B1, results in effects similar to ectopic CYP1B1 expression [30].